Oral Prednisone Speeds Uveitis Inflammation Control

A retrospective study of 462 patients links oral prednisone added to eye drops with faster control of HLA-B27-associated uveitis inflammation.

Updated on Nov. 4, 2026 in Arthritis

Bold flat-color editorial illustration of a round white tablet beside an amber dropper bottle and a simple stylized eye outline on a cream field. — Researchers reported in the American Journal of Ophthalmology that adding oral prednisone to steroid eye drops was linked to faster control of uveitis inflammation in 462 patients. AI Illustration. Upload story photo >

Researchers reported in the American Journal of Ophthalmology on November 2, 2026, that adding oral prednisone to topical corticosteroid eye drops was linked to faster control of inflammation in HLA-B27-associated acute anterior uveitis. The retrospective study analyzed one eye each of 462 patients seen from 2014 to 2025.

Why it matters

Acute anterior uveitis is an inflammatory eye condition that can be associated with HLA-B27, a genetic marker linked to certain forms of arthritis. The findings suggest a possible option for patients whose inflammation does not improve on drops alone, though the study is retrospective.

The retrospective review of 462 patients found a median time to complete control of 28 days with oral prednisone plus eye drops versus 41 days with drops alone, with an adjusted hazard ratio of 2.19. Whether these associations hold in prospective trials has not been determined.

The players

Bascom Palmer Eye Institute

A specialized eye care and research institute affiliated with the University of Miami's Miller School of Medicine, based in Miami, where the patients were treated.

The details

Of 74 patients who received oral prednisone, the median starting dose was 60 mg, typically started after inflammation failed to improve or worsened on drops. Time to stopping all corticosteroids was 62 days with prednisone and 61 days without, a difference that was not statistically significant (P = .505).

2014 to 2025: Patients were seen during the period covered by the retrospective study.
November 2, 2026: The study was published online in the American Journal of Ophthalmology.

Health Landscape

The findings add to ongoing clinical work at Bascom Palmer Eye Institute on uveitis treatment strategies, a field where corticosteroids remain the standard first-line therapy. The study's short-course suggestion would need prospective validation before reshaping standard care.

Patients with HLA-B27-associated uveitis may want to ask their eye doctor whether an oral corticosteroid add-on is appropriate if drops alone are not controlling inflammation. Any use of prednisone should be decided with an ophthalmologist because of its systemic side effects.

The takeaway

Inflammation that persists on eye drops is worth reporting to an eye specialist promptly, since early control may shorten the course of treatment. Patients should discuss any systemic medication options with their care team before starting them.